Keros Therapeutics, Inc.

NasdaqGM:KROS Voorraadrapport

Marktkapitalisatie: US$2.3b

Keros Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Keros Therapeutics is Jas Seehra, benoemd in Dec2015, heeft een ambtstermijn van 8.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.93M, bestaande uit 7.3% salaris en 92.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.62% van de aandelen van het bedrijf, ter waarde $ 14.14M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 4.7 jaar.

Belangrijke informatie

Jas Seehra

Algemeen directeur

US$8.9m

Totale compensatie

Percentage CEO-salaris7.3%
Dienstverband CEO8.9yrs
Eigendom CEO0.6%
Management gemiddelde ambtstermijn3.4yrs
Gemiddelde ambtstermijn bestuur4.7yrs

Recente managementupdates

Recent updates

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Nov 20
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Jun 10

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Apr 23
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Sep 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Jun 10
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13
Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19
We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Nov 27
Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Keros Therapeutics prices equity offering at $50

Nov 13

Analyse CEO-vergoeding

Hoe is Jas Seehra's beloning veranderd ten opzichte van Keros Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$182m

Jun 30 2024n/an/a

-US$168m

Mar 31 2024n/an/a

-US$160m

Dec 31 2023US$9mUS$649k

-US$153m

Sep 30 2023n/an/a

-US$142m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$116m

Dec 31 2022US$6mUS$611k

-US$105m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$79m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$7mUS$557k

-US$59m

Sep 30 2021n/an/a

-US$61m

Jun 30 2021n/an/a

-US$53m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$10mUS$521k

-US$45m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$695kUS$485k

-US$14m

Compensatie versus markt: De totale vergoeding ($USD 8.93M ) Jas } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.50M ).

Compensatie versus inkomsten: De vergoeding van Jas is gestegen terwijl het bedrijf verliesgevend is.


CEO

Jas Seehra (68 yo)

8.9yrs

Tenure

US$8,932,076

Compensatie

Dr. Jasbir S. Seehra, also known as Jas, Ph D., has been Chief Executive Officer and Director at Keros Therapeutics Inc., since December 2015 and is its Chair of the Board since July 1, 2024 and was its Pr...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Jasbir Seehra
CEO & Chair of the Board8.9yrsUS$8.93m0.62%
$ 14.1m
Christopher Rovaldi
President & COO2.8yrsUS$4.69m0%
$ 0
Keith Regnante
Chief Financial Officer4.8yrsUS$2.20m0%
$ 0
Esther Cho
Senior VP4.6yrsgeen gegevensgeen gegevens
Robin Wagner
Senior Vice President of Human Resources3.4yrsgeen gegevensgeen gegevens
John Oram
Senior Vice President of Program & Portfolio Management1.6yrsgeen gegevensgeen gegevens
Yung Chyung
Chief Medical Officerno datageen gegevensgeen gegevens

3.4yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van KROS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Jasbir Seehra
CEO & Chair of the Board8.9yrsUS$8.93m0.62%
$ 14.1m
Carl Gordon
Independent Director4.7yrsUS$409.37kgeen gegevens
Tomer Kariv
Independent Director4.8yrsUS$385.86kgeen gegevens
Jean-Jacques Bienaime
Lead Independent Directorless than a yeargeen gegevens0.00049%
$ 11.1k
Julius Knowles
Independent Director8.6yrsUS$388.48k0.0029%
$ 66.6k
Mary Gray
Independent Director3.9yrsUS$396.98k0.11%
$ 2.4m
Ran Nussbaum
Independent Director8.6yrsUS$390.56k0%
$ 0
Alpna Seth
Independent Director1.5yrsUS$1.02m0.041%
$ 931.9k
Nima Farzan
Independent Director4.7yrsUS$388.48k0.087%
$ 2.0m
Mary Bouxsein
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Vicki Rosen
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Paul Yu
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

4.7yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KROS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).